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A B S T R A C T
Arrhythmias in the athlete can range from benign and asymptomatic to highly symp-
tomatic and life-threatening. There is risk of not diagnosing an important cardiovas-
cular condition which may predispose to a serious or life threatening arrhythmia. At 
the same time there is the risk of unnecessarily restricting the athlete with a more 
benign condition. Sudden cardiac death in the athlete, although relatively uncommon, 
remains a challenge as the screening techniques for identification of individuals at risk 
are insensitive. Many of the underlying cardiovascular diseases responsible for sudden 
death with exercise can be identified. These include hypertrophic cardiomyopathy, ar-
rhythmogenic right ventricular dysplasia, Wolff-Parkinson-White syndrome, anoma-
lous origin of the coronary artery, and the inherited long QT syndromes. To prevent 
fatalities and unnecessary restriction on athletic participation, the best available in-
formation has recently been updated with consensus recommendations and guidelines 
regarding eligibility. In this manuscript the cardiovascular conditions and cardiac ar-
rhythmias that predispose to sudden cardiac death in the athlete are discussed.
I N T R O D U C T I O N
Sudden cardiac death in the athlete has intrigued the medical community and 
the public since the initial report of the unexpected death of the Greek soldier 
Phoedippides on completing his historic run from Marathon to Athens to deliver 
the message of victory over the Persians in 490 B.C. To the extent that these deaths 
occur in the healthiest segment of society, the unexpected death of an athlete is a 
tragic irony. Because sudden cardiac death in the athlete is relatively uncommon and 
the screening techniques for identification of individuals at risk are insensitive, the 
problem of sudden death remains a challenge. Many of the underlying cardiovas-
cular diseases responsible for sudden death with exercise are now identified. These 
include hypertrophic cardiomyopathy, arrhythmogenic right ventricular dysplasia, 
Wolff-Parkinson-White Syndrome, anomalous origin of the coronary artery, and the 
inherited long QT syndromes. To prevent fatalities and unnecessary restriction on 
athletic participation, the best available information has recently been updated with 
consensus recommendations and guidelines regarding eligibility. In this manuscript, 
we will discuss the cardiovascular conditions and cardiac arrhythmias that predispose 
to sudden cardiac death in the athlete.1-9
Arrhythmias in the athlete can run a range of risk from benign and asymptomatic 
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to highly symptomatic and life-threatening. There is risk of 
not diagnosing an important cardiovascular condition which 
may predispose to a serious or life threatening arrhythmia. 
At the same time there is the risk of unnecessarily restricting 
the athlete with a more benign condition. Furthermore, the 
evaluation of the athlete is confounded by many complex, 
psychological, social and in some instances, economic impli-
cations. Benign arrhythmias such as many bradyarrhythmias 
and atrial and ventricular premature contractions are common 
in the young and older athlete. Supraventricular arrhythmias 
such as atrial fibrillation, atrioventricular nodal re-entrant 
tachycardia, and the Wolff-Parkinson-White syndrome are 
less common. The least common, but clearly the most impor-
tant to diagnosis and treat appropriately, are life threatening 
ventricular arrhythmias which may predispose the patient to 
a clinical syndrome of sudden cardiac death. Although the 
annual risk of sudden death in the athlete appears to be low 
(between 5 and 10 athletes for each 1 million participants 
per year), selected athletes such as those with hypertrophic 
cardiomyopathy may be at particularly high risk.
e vA l U A T I O N  A N D  M A N A g e M e N T
Evaluation and management of the athlete at the time of 
screening physical exam or when presenting with symptoms 
of a cardiac arrhythmia begins with a detailed history. The 
physician should always ask the individual whether they have 
palpitations, lightheadedness, “skipped beats”, “extra beats”, 
presyncope or syncope. When symptoms are present, the 
physician should determine whether these are associated 
with exertion, post-exertion or at rest. In general, symptoms 
of an arrhythmia which occur with exertion are more likely 
to be serious than those occurring at rest. Rarely a neurocar-
diogenic reflex can be the cause of syncope during exertion. 
The duration and frequency of the symptoms are important. 
In this respect, symptoms that are frequent and sustained 
(lasting greater than 30 seconds) are probably less likely to be 
serious or life-threatening compared to those that are short 
lived and shorter in duration. The decision to further evalu-
ate the athlete with symptoms possibly due to an arrhythmia 
needs to be made in the context of the patient’s family history 
of any significant cardiovascular condition or premature sud-
den death and the presence or absence of any structural heart 
disease in the athlete. In general, when an athlete presents with 
symptoms consistent with a more serious arrhythmia, such as 
sudden onset, syncope, exertionally related symptoms or injury 
associated with the arrhythmia, a full evaluation is warranted. 
By contrast in the athlete with symptoms which suggest a less 
serious condition, such as post-exertional lightheadedness or 
orthostatic symptoms, it may be appropriate to undertake a 
more limited evaluation.
Premature ventricular contractions and nonsustained 
VT in the absence of structural heart disease, generally have 
no prognostic significance and need to be treated only if the 
symptoms are moderate or severe. However, in the presence of 
structural heart disease, nonsustained ventricular tachycardia, 
or sustained ventricular tachycardia could be a marker of risk 
for sudden cardiac death.
C A R D I O vA S C U l A R  C O N D I T I O N S  P R e D I S P O S I N g 
T O  S U D D e N  D e A T h
In the younger athlete (less than 35 years of age) hyper-
trophic cardiomyopathy is the most commonly underlying 
structural heart disease predisposing to sudden cardiac death. 
In fact, hypertrophic cardiomyopathy accounts for up to 50% 
of the sudden deaths in young athletes in North America. 
Anomalous origin of the coronary arteries, arrhythmogenic 
right ventricular dysplasia, as well as a number of less common 
conditions causing sudden death in the athlete are listed in 
Table 1. In the athlete older than 35 years of age, coronary 
artery disease is the underlying condition which predisposes 
to sudden death and over 75% of patients. By contrast, the 
experience in Italy is that arrhythmogenic right ventricular 
dysplasia more commonly predisposes to sudden cardiac death 
in the young athlete than hypertrophic cardiomyopathy.
TABle 1. Cardiovascular Conditions Associated with Sud-
den Cardiac Death in the Athlete
 Hypertrophic cardiomyopathy
 Coronary artery disease
 Arrhythmogenic right ventricular dysplasia
 Left ventricular hypertrophy
 Myocarditis
 Conduction system abnormalities
 Mitral valve prolapse
 Congential heart disease
 Valvular heart disease
 Aortic dissection
 Cerebral embolus
 Pulmonary embolus
 Arteriovenous malformation
 Berry aneurysm
 Wolff-Parkinson-White syndrome
 Myocardial bridge
 Coronary aneurysm
 Subvalvular aortic stenosis
 Long QT syndrome
 Idiopathic ventricular fibrillation
 Dilated cardiomyopathy
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S U P R A v e N T R I C U l A R  A R R h y T h M I A S
Supraventricular arrhythmias are not more common in 
the athlete with the possible exception of atrial fibrillation. 
Additionally supraventicular arrhythmias rarely predispose 
to sudden death (Table 2). However, atrial fibrillation in the 
presence of Wolff-Parkinson-White Syndrome rarely allows 
conduction to the ventricle with ventricular rates greater than 
250 beats/minute. Rarely with intense physical exertion this 
may predispose to ventricular fibrillation in an ortherwise nor-
mal heart. Atrial fibrillation in the presence of hypertrophic 
cardiomyopathy can result in loss of atrial contraction, lower-
ing of cardiac output and hemodynamic collapse.
Atrial fibrillation or flutter in the athlete is felt to be more 
common compared to an aged match population of non-ath-
letes. Vagally medially atrial fibrillation may be more common 
in athletes. Athletes presenting with atrial fibrillation or flutter 
should undergo a comprehensive history and physical ex-
amination including a detailed history with regard to alcohol, 
caffeine or illicit drug use, an EKG, an echocardiogram and 
TSH to screen for thyroid abnormalities. If the individual is in 
sustained atrial fibrillation or flutter, the maximal ventricular 
response should be assessed with an exercise stress test and 
ambulatory monitoring while the patient is exercising during 
atrial fibrillation.
Wolff-Parkinson-White (WPW) syndrome, manifesting 
with ventricular pre-excitation in the form of a delta wave is 
another cause of supraventricular arrhythmias in the athlete.10 
A delta wave is found in approximately 3 out of 1,000 indi-
viduals . The evaluation of the athlete, or any individual with 
asymptomatic ventricular pre-excitation or WPW pattern on 
the surface EKG remains controversial. Some electrophysiolo-
gists recommend observation without restriction of athletic 
participation since the risk of sudden death appears to be 
extremely low. Because the WPW syndrome is associated with 
some congenital abnormalities such as Epstein’s anomaly, it 
is generally agreed that a history, physical examination, 12-
lead EKG, 24-hour ambulatory monitoring, stress test, and 
echocardiography should be performed to exclude associated 
cardiovascular abnormalities. .Some experts recommend 
electrophysiological evaluation in the asymptomatic athlete 
with WPW to define the properties and location of the by-
pass tract. If conduction to the ventricle is present through 
the bypass tract at rates greater than 240 bpm, consideration 
should be given to radiofrequency ablation to eliminate the 
risk of future life threatening arrhythmias.11 Athletic restric-
tions are not generally recommended for the asymptomatic 
individual with WPW.
TABle 2. Supraventricular Arrhythmias in the Athlete
Arrhythmia
Baseline
eCg Symptoms Diagnosis Treatment Options
guidelines for Athletic 
Participation1,2
APCs Often WNL Palpitations Monitor Reassurance No restrictions beta-blocker if highly 
symptomatic
Atrial Fib Often WNL Palpitations Monitor Antiarrhythmics
Anticoagulation & with warfarin
Rate control
Bodily contact prohibited
Atrial Flutter Often WNL Palpitations Monitor RFA
Antiarrhythmics
Rate control & Anticoagulation
Bodily contract prohibited prohibited 
with warfarin
Ventricular
Preexcitation 
(WPW)
Short PR
Delta waves 
Asymptomatic Monitor
ECG
EPS
No therapy
RFA if high risk
Consider EPS to risk stratify
Ventricular 
Preexcitation
(WPW)
Short PR
Delta waves
Palpitations Monitor
ECG
RFA
Antiarrhythmias
No restrictions after 3-6 month 
without symptoms
AVNRT Normal Palpitations Monitor
EPS
RFA
Antiarrhythmics
No restrictions after 3-6 months 
without symptoms
APC=atrial premature contractions; AVNRT=atrioventricular nodal re-entrant tachycardia-within normal limits; ECG=Electrocardiogram; 
EPS=electrophysiology study, RFA=radiofrequency ablation; WNL=within normal limits; WPW=Wolf-Parkinson-White Syndrome (Modified 
from Ref 3). 
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v e N T R I C U l A R  A R R h y T h M I A S
In evaluating the athlete with ventricular arrhythmias, the 
nature of the ventricular arrhythmia, the presence or absence 
of symptoms and the presence or absence of structural heart 
disease are critical factors in determining the need for therapy 
or restriction from athletic activity. Most commonly, individu-
als at risk for sudden cardiac death have underlying structural 
heart disease, with hypertrophic cardiomyopathy being the 
most common. Ventricular arrhythmias in the setting of com-
mon types of congenital heart disease such as arrhytmogenic 
right venrticular dysplasia, 12 Epstein’s anomaly, tetralogy of 
Fallot, or other valvular heart disease also are markers for a 
higher risk for sudden cardiac death. Additionally, idiopathic 
dilated cardiomyopathy and acute myocarditis are accepted 
as conditions associated with a higher risk of life threatening 
arrhythmic events
Premature ventricular contractions (PVCs) in the athlete 
are felt to be common and rarely cause sufficiently severe 
symptoms to warrant therapy. In the absence of any congenital 
or acquired structural heart disease, there is no increased risk 
of life threatening arrhythmias. Routine evaluation of athletes 
with premature ventricular contractions includes history, phys-
ical examination, EKG as well as echocardiogram. If there is 
no evidence of hypertrophic cardiomyopathy, arrhythmogenic 
right ventricular dysplasia, anomalous origin of the coronary 
arteries, coronary artery disease, dilated cardiomyopathy 
or myocarditis or long QT syndrome, the PVCs are benign 
and are not a marker of risk for sudden cardiac death (SCD). 
When there is no underlying structural heart disease, therapy 
with beta blockers may decrease symptoms with or without 
reduction in the frequency of PVCs. Drug therapy with other 
antiarrhythmic agents generally is not needed unless the 
symptoms are sufficiently severe and persistent on beta blocker 
therapy. In the absence of symptoms, and in the absence of 
structural heart disease, no therapy is needed.
Without structural heart disease, nonsustained ventricu-
lar tachycardia does not indicate any additional risk of more 
serious or life threatening cardiac arrhythmias or sudden 
cardiac death The evaluation and management of athletes 
with nonsustained ventricular tachycardia is similar to those 
with premature ventricular contractions with a few notable 
exceptions. In those athletes with nonsustained polymorphic 
ventricular tachycardia, there may be a higher risk for life 
threatening ventricular arrhythmias. Beta blocker therapy is 
considered to be the first approach to these individuals and 
restriction from athletic activity should be considered. When 
an athlete has had a prior episode of sustained ventricular 
tachycardia or prior episodes of ventricular fibrillation, a 
thorough evaluation of cardiac status with history, physical, 
EKG, echocardiogram and selected use of stress test, cardiac 
magnetic resonance imaging (MRI), cardiac catheterization, 
and electrophysiological (EP) evaluation is warranted. Subsets 
of sustained ventricular tachycardia originating from the right 
ventricular outflow tract or other regions of the right or left 
ventricle (idiopathic ventricular tachycardia) typically occur 
in the absence of any identifiable structural heart disease. 
In this setting, there is extremely low risk for sudden cardiac 
death. Programmed ventricular stimulation, sometimes sup-
plemented by isoproterenol infusion generally can induce 
the sustained arrhythmia. When induced, mapping the site 
of origin and cure with radiofrequency ablation is generally 
possible. As with athletes who undergo ablative therapy for 
supraventricular arrhythmias, these athletes can return to 
athletic competition after a period of approximately 3 months 
free of arrhythmias.
In athletes presenting with sustained ventricular tachycar-
dia or prior episodes of resuscitated ventricular fibrillation 
there is generally some type of underlying structural heart 
disease. In the athlete under age 35, hypertrophic cardiomy-
opathy, anomalous origin of the right coronary artery, right 
ventricular dysplasia, or other congenital abnormalities typi-
cally serves as a substrate for these arrhythmias. By contrast, in 
athletes older than 35 years of age, over 80% have underlying 
coronary disease with an ischemic basis for their arrhythmias. 
In these athletes, the implantable cardioverter defibrillator 
(ICD) has been shown to provide superior protection for sud-
den death prevention to antiarrhythmic therapy particularly 
in the setting of underlying coronary artery disease. Once 
an athlete with underlying structural heart disease has had 
episodes of sustained ventricular tachycardia or fibrillation, 
and receives an ICD, competitive sports are prohibited by 
current guidelines.
Exercise has been noted to exacerbate arrhythmias in 
many types of structural heart disease that predispose to sud-
den cardiac death.13 In cases of sustained monomorphic ven-
tricular tachycardia associated with right ventricular dysplasia 
and ventricular tachycardia of right ventricular outflow tract 
origin occurring in the absence of structural heart disease, 
exercise frequently exacerbates the arrhythmia. In patients 
with anomalous origin of the coronary arteries and congenital 
long QT syndrome, life threatening ventricular arrhythmias 
frequently occur with exertion or immediately afterwards. 
With the most common form of underlying structural heart 
disease, hypertrophic cardiomyopathy, arrhythmias are in-
duced by exertion in approximately one-half of individuals. In 
patients with idiopathic ventricular fibrillation, approximately 
15% of individuals have their cardiac arrest in the setting of 
intense physical exertion. In addition, in the setting of underly-
ing coronary artery disease, there is a multi-fold increase in 
the frequency of sudden death related to exertion.
w O R K U P  f O R  v e N T R I C U l A R  A R R h y T h M I A S
Because sudden death rarely occurs in an athlete with 
a structurally normal heart, an assessment for structural 
heart disease is of paramount importance in the evaluation 
of athletes with possible cardiac symptoms (Table 3). A tran-
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sthoracic echocardiogram and resting electrocardiogram is 
generally a sufficient workup for structural heart disease, 
although individuals with anomalous coronary arteries will 
not be found. Individual with risk factors for coronary artery 
disease (older age, male gender, high cholesterol, family 
history of early coronary artery disease, diabetes, hyperten-
sion, and smoking) should, in addition undergo an exercise 
stress test. In the absence of structural heart disease the only 
symptoms concerning for an increased risk of sudden death 
are patients with resuscitated sudden death and no structural 
heart disease, patients with syncope and a family history of 
sudden death, and patients with syncope at peak exercise. In 
most patients, structural heart disease can be diagnosed by an 
electrocardiogram, an echocardiogram, and an exercise stress 
test in patients over 35 years of age. However, the diagnosis of 
anomalous coronary arteries can be difficult and may require 
cardiac catheterization.
Genetic
Because many of the cardiac diseases that predispose to 
sudden death in athletes are genetic in origin, the family medi-
cal history is also important. These genetic disorders include 
hypertrophic cardiomyopathy, long QT syndrome, coronary 
artery disease, the Brugada syndrome and even some types 
of arrhythmogenic right ventricular dysplasia and idiopathic 
dilated cardiomyopathy. Therefore, the presence of early sud-
den death or hereditary cardiac abnormality in the family of 
an athlete should prompt a thorough cardiac workup regard-
less of the presenting symptoms. At the current time genetic 
screening is evolving rapidly and may become commercially 
available to assist in the diagnosis.
Invasive electrophysiologic evaluation
An invasive electrophysiologic evaluation is often per-
formed in patients with coronary artery disease in order to 
ascertain the risk of future arrhythmias and whether patients 
should receive treatment for ventricular arrhythmias. These 
studies require transvenous catheters to be placed in the right 
ventricle and atrium and electrical stimulation of the heart. In 
patients with coronary artery disease, electrophysiologic evalu-
ation is of reasonably high sensitivity (90-95%) and specificity 
(95%) for the induction of monomorphic ventricular tachy-
cardia. However, the significance of induced nonsustained 
ventricular tachycardia and ventricular fibrillation is less well 
established. In patients with arrhythmogenic right ventricular 
dysplasia the sensitivity of electrophysiologic evaluation is 70 
to 80%, and the specificity although thought to be reasonable, 
is not clearly defined.
Unfortunately, the sensitivity and specificity of an invasive 
electrophysiologic evaluation is low in patients with hyper-
trophic cardiomyopathy, idiopathic dilated cardiomyopathy, 
long QT syndrome, and congenital heart disease, which are 
the most common in young individuals dying suddenly, as 
well as in individuals with normal hearts. Thus, electrophysi-
ologic evaluation in athletes with coronary artery disease and 
arrhythmogenic right ventricular dysplasia is a useful tool to 
evaluate symptoms, prognosticate future events, and guide 
treatment. However, in athletes with cardiac conditions other 
than coronary artery disease, an electrophysiologic evaluation 
cannot be relied upon to prognosticate or guide therapy.
T R e A T M e N T
Athletes with Documented Ventricular Arrhythmias
Treatment options for ventricular arrhythmias in athletes 
include antiarrhythmic agents, ablation, and implantable 
cardioverter defibrillators (ICDs) (Table 4). In patients with 
life-threatening ventricular arrhythmias, ICDs have been 
shown to be superior to antiarrhythmic drugs. In addition 
TABle 3. Diagnosis and management of ventricular arrhythmias in athlete
Condition Symptoms eCg Diagnosis Treatment Options Competitive Athletics
VPCs Palpitations NL Monitor Reassurance No restrictions
NSVT Palpitations Often NL Monitor Assess for SHD
If no SHD, reassure
If SHD, further
Evaluation is needed
No restrictions if no SHD. If SHD present, see table
VT/VF Palpitations Can be NL Monitor RFA if no SHD
ICD or AAD
If SHD present
No restrictions if no SHD and cure by RFA
Restricted to low intensity sports for all others
Recommendations for competitive athletics are based on the 26th Bethesda Conference. ECG=electrocardiogram; VPC=ventricular premature 
contractions; NL=normal; SHD=structural heart disease; BB=beta-blockers; NSVT=nonsustained ventricular tachycardia; VT=ventricular 
tachycardia; VF=ventricular fibrillation; RFA=radiofrequency ablation; ICD=implantable cardioverter defibrillator; AAD=antiarrhythmic 
drugs. (Modified from Ref. 3)
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TABle 4. Ventricular Arrhythmias in Different Forms of Structural Heart Disease
Condition Symptoms eCg vT morph Treatment Options Competition Athletics
Idiopathic Palpitations LH, 
syncope
NL RB, left axis RFA No restrictions 3 months  
after RFA
Idiopathic RVOT, 
VT
Palpitations LH, 
syncope
NL LB, inf axis RFA No restrictions 3 months  
after RFA
HCM Palpitations
Syncope
SCD
Q’s-ant BB
AAD
Myomectomy
ICD
Only low intensity
ARVD Palpitations
Syncope
SCD
T=inv ant
RBBB
Epsilon wave
LB, inf axis Sot or amio
ICD
RFA
Only low intensity
CAD Palpitations
Syncope
SCD
Infarcts
Ischemic ST
RB or LB
ICD
AAD Only low intensity
LQTS Palpitations
Syncope
SCD
Long QTc Torsades de 
pointes
BB
PPM
ICD
Only low intensity
Anomalous CAD SCD NL VF CABG No restrictions after CABG
=electrocardiogarm; VT=ventricular tachycardia; LV=left ventricle; LH=lightheadedness; NL=normal; RB=right bundle; RFA=radiofrequency 
ablation; RVOT=right ventricle outlow tract; VT=ventricular tachycardia; LB=left bound; HCM=hypertrophic cardiomyopathy; SCD=sudden 
cardiac death; BB=beta-blockers; AAD=antiarrhythmic drugs; ICD=implantable cardioverter defibrillator; ARVD=arrhythmogenic right 
ventricular dysplasia; RBBB=right bundle branch block; LBBB=left bundle branch block; sot=sotalol; amio=amiodarone; PPM=permanent 
pacemaker; CABG=coronary artery bypass surgery. (Modified from Ref. 3)
antiarrhythmic agents are increasingly being feared as the 
potential for proarrhythmia is realized. In general, any athlete 
with a documented ventricular arrhythmia has a potentially 
life-threatening arrhythmia. The exception would lie in those 
patients with no underlying heart disease and idiopathic left 
ventricular tachycardia or right ventricular outflow tract 
ventricular tachycardia. In these patients without structural 
heart disease, cure rates with radiofrequency ablation ap-
proach 90%. These athletes with no structural heart disease 
and a successful ablation of ventricular tachycardia that is 
without recurrence for 6 months are allowed to participate 
in athletics.
A T h l e T e S  w I T h O U T  D O C U M e N T e D 
v e N T R I C U l A R  A R R h y T h M I A S
Athletes with structural heart disease known to put them 
at risk for sudden death, but without ventricular arrhythmias 
or symptoms of ventricular arrhythmias (i.e. syncope or pr-
esyncope) are a more difficult group to advise and treat. If they 
have documented hypertrophic cardiomyopathy, idiopathic 
dilated cardiomyopathy, arrhythmogenic right ventricular 
dysplasia or congenital heart disease, competitive athletics 
of moderate and high intensity are generally prohibited. In 
the athlete with hypertrophic cardiomyopathy, risk factors 
for sudden cardiac death include family history of sudden 
death presentation with syncope or sudden death, inducible 
ventricular arrhythmias and septal thickness >30 mm. Sponta-
neous nonsustained ventricular tachycardia as a risk factor for 
sudden death is controversial and may not be an independent 
risk factor. In hypertrophic cardiomyopathy patients with one 
risk factor for sudden death, implantation of the ICD can be 
considered. With more risk factors, the ICD should be more 
strongly advised.
Arrhythmogenic right ventricular dysplasia patients with 
inducible ventricular tachycardia at ventricular stimulation, 
drug failure during serial testing, irregular antiarrhythmic 
drug intake, previous cardiac arrest, and presence of late 
potentials on signal averaged electrocardiograms are at in-
creased risk for ventricular arrhythmias. Many patients with 
arrhythmogenic right ventricular dysplasia will meet one of 
these criteria. Risk factors for sudden cardiac death include 
presentation with syncope and markedly depressed right 
ventricular function. Furthermore, arrhythmogenic right 
ventricular dysplasia is a progressive disease and the patient’s 
SUDDEN DEATH IN THE ATHLETE
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risk of sudden cardiac death may increase with time. In the 
patient with arrhythmogenic right ventricular dysplasia op-
tions for treatment include antiarrhythmic agents, ablation, 
and ICDs. As arrhythmogenic right ventricular dysplasia is a 
likely progressive disease, treatments effective at one point 
may become ineffective later in time. Radiofrequency abla-
tion is often acutely successful but recurrences of ventricular 
tachycardia are common and sudden death is described. Cur-
rent opinions of the optimal treatment of these patients vary, 
but in those of sufficiently high risk for sudden death an ICD 
should be considered. Moderate and high level competitive 
athletics are contraindicated, in view of the frequent provoca-
tion of arrhythmias with exercise.
Although some studies have shown an increased risk of 
sudden death in idiopathic dilated cardiomyopathy in patients 
with nonsustained ventricular tachycardia and inducible ar-
rhythmias, the most important factor is the degree of left 
ventricular dysfunction. The presence of syncope may also 
increase the risk of sudden death. In the patient with idiopathic 
dilated cardiomyopathy, class 1 antiarrhythmic agents are 
rarely effective and are possibly toxic and should generally 
be avoided. Beta-blockers are probably effective and should 
be prescribed to all patients that can tolerate them. Amio-
darone may have the highest efficacy of all antiarrhythmic 
agents for life-threatening ventricular arrhythmias in this 
condition. In asymptomatic patients with idiopathic dilated 
cardiomyopathy, therapy other than beta-blockers and ACE-
inhibitors are not generally recommended. However, in the 
athlete with syncope and idiopathic dilated cardiomyopathy, 
an ICD should be considered. In those patients with idiopathic 
dilated cardiomyopathy and spontaneous sustained ventricular 
arrhythmias competitive athletics of moderate or high intensity 
should be avoided.
Athletes with the long QT syndrome are at increased risk 
of sudden death if there is a family history of sudden death, 
if they personally have had syncope or sudden cardiac death 
or if bradycardia is present. Beta-blockers should be an initial 
therapy in all patients with the long QT syndrome. Permanent 
pacemakers should be used when bradycardia occurs with 
beta-blocker therapy or when recurrent symptoms occur on 
beta-blockers. More controversial treatments include gangli-
onectomy and ICD therapy.
In athletes with coronary artery disease, risk factors for 
sudden cardiac death include >10 premature ventricular 
contractions/hour, nonsustained ventricular tachycardia, 
inducible ventricular tachycardia, low left ventricular ejection 
fraction, abnormal signal averaged ECG, and decreased heart 
rate variability. The MADIT study has shown that patients 
with low left ventricular ejection fractions and inducible ven-
tricular arrhythmias have an improved survival when treated 
with ICDs. However, patients with coronary artery disease 
and preserved ejection fractions do not generally require 
ventricular stimulation or ICDs in the absence of syncope or 
resuscitated sudden death. Indeed, athletic participation can 
reduce the risk of recurrent myocardial infarctions and pos-
sibly sudden death. In athletes with coronary artery disease 
and ventricular arrhythmias only low intensity competitive 
athletics are permitted.
In asymptomatic athletes with anomalous coronary arter-
ies, a maximal exercise stress test is advised. However, since 
sudden death occurs without symptoms in 50% of the individu-
als, a normal exercise test does not automatically confer low 
risk. Most of the deaths occurring with anomalous coronary 
arteries occur with exertion. If an athlete has been diagnosed 
with anomalous coronary arteries, surgical therapy should be 
considered. If revascularization is undertaken and the patient 
has no inducible myocardial ischemia a return to competitive 
athletics can be allowed.
A U T O M A T I C  e x T e R N A l  D e f I B R I l l A T O R S
Automatic external defibrillators, first introduced for 
clinical use in 1979, have revolutionized the approach to out 
of hospital cardiac arrest, with clear implications for their 
use at athletic events.14 An AED is a lightweight portable 
device containing a battery, capacitors, and circuitry design 
to analyze cardiac rhythm and prompt the operator when a 
shock is indicated for a life threatening ventricular arrhyth-
mia. Manufacturers were challenged by the American Heart 
Association to develop a device so reliable in its sensitivity 
and specificity for life threatening heart rhythms and so easy 
to use that fear of misuse and inappropriate shocks would be 
unfounded. Reductions in size, weight, cost and maintenance 
by manufacturers have allowed these devices to be incorpo-
rated into the American Heart Associations Public Access to 
Defibrillation Programs
The concept of Public Access to Defibrillation promotes 
expansion of the role of the defibrillation to both the minimally 
trained first responder, such as the trainers, coaches, police 
officers, fire fighters, security guards and flight attendants, 
and trained lay persons who are present at the time of arrest. 
It also promotes the placement of the AED in such areas as 
sports arenas, athletic fields, airports, convention centers, 
casinos, shopping malls, large office buildings and airlines. 
It is possible that the AED will become as common place as 
a fire extinguisher in the future. There is a growing body of 
evidence to suggest that the public access the defibrillation 
using the AED has resulted in greatly improved survival for 
sudden cardiac arrest
Cardiac arrest in athletics may occur in a variety of set-
tings that should be considered in designing a response sys-
tem for these emergencies. Most of the reported episodes of 
sudden cardiac arrest in athletes occur in those participating 
in football or basketball. Accordingly, a logical focus of the 
AED use of a response system would be on these two sports. 
In addition, it is well appreciated that more than half of the 
emergencies occurred during training sessions as opposed 
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to the actual competition. It is widely accepted that the team 
athletic trainers, rather than team physicians are most likely 
to be present during these sessions. Approximately 1/3 of 
episodes of sudden cardiac arrest occur in athletes during 
or immediately after a team competition when a physician is 
most likely to be present. Importantly, cardiac emergencies 
also frequently develop amongst spectators attending the 
athletic event. In fact, the probability of use of an AED and 
frequency of such emergencies is likely greater in the specta-
tors and other attendees than it is in the athletic participant. 
An AED needs to be incorporated into a formal response 
system that adheres to the principles in the chain of survival 
promoted by the American Heart Association. This concept 
of chain of survival is straightforward with early activation of 
emergency medical care, early CPR, early defibrillation using 
the AED and early advanced life support
Multiple studies have demonstrated that EMTs and 
paramedics can effectively and safely use manual defibrilla-
tors. A small number of studies have shown that use of the 
AED was safe and effective. There has been a suggestion of 
a possible survival advantage with the use of AED. Multiple 
studies documented improved survival with addition of EMT 
defibrillation using the AED. These multiple studies also have 
documented that use by emergency personal such as police 
officers, fire fighters and trained first responders dramatically 
reduce the time to defibrillation and enhance the survival in 
selected.
Clinical experience with AEDs at public schools and ath-
letic facilities are currently being evaluated. However, efficacy 
and cost-effectiveness data are not yet available. National 
programs which are designed to support AED use in schools 
and athletic events include Project Adam in Wisconsin. This 
program has already resulted in placement of AEDs in 10-15% 
of the regions high schools and has reportedly already saved a 
life. The Gregory Mayor Fund of Pennsylvania has resulted in 
placement of AEDs within many high schools in the county. In 
addition, legislation has resulted in funding for placement of up 
to two AEDs per high school statewide (Pennsylvania House 
Bill 996). In Boston, Massachusetts, Operation Heartbeat has 
provided AEDs for one public high school per district. In all of 
the programs, AEDs will be incorporated into a coordinated 
emergency response system that includes training for initia-
tion of bystander CPR, and immediate activation of bystander 
cardiopulmonary resuscitation. While more cost effectiveness 
data is needed, athletic organization, educational institutions, 
coaches, sports medicine physicians, trainers and emergency 
personal should give serious consideration to incorporation 
of AEDs into an emergency response system.
C O N C l U S I O N
Sudden cardiac death in the athlete is rare, albeit tragic, 
event.1-23 The majority of deaths are due to underlying struc-
tural heart disease. In young athletes (<35 years old), the lead-
ing causes are hypertrophic cardiomyopathy, right ventricular 
cardiomyopathy, and congenital coronary artery anomalies, 
while less common are primary electrical diseases, such as the 
WPW syndrome or the long QT syndrome. In older athletes 
(over 35 years old) most deaths are due to coronary artery 
disease. Those with documented life-threatening ventricular 
arrhythmias or with underlying heart disease and high risk 
of developing sudden death can now be protected with an 
implantable cardioverter defibrillator. Cardiology Societies 
have put forth pre-participation screening strategies aim-
ing at reducing these tragic events. Wider availability of the 
automatic external defibrillator may help save lives during 
sporting activities.
R e f e R e N C e S
 1. Zipes DP, Garson A Jr. Task Force 6. In 26th Bethesda Confer-
ence. Recommendations for determining eligibility for compe-
tition in athletes with cardiovascular abnormalities. Maron BJ, 
Mitchell J, eds. J Am Coll Cardiol 1994;24:892-899.
 2. Estes NAM III, Link MS, Cannom D, et al. NASPE consensus 
statement report of the NASPE policy conference on arrhythmi-
as and the athlete. J Cardiovascular Electrophysiol 2001:12;1208-
1218.
 3. Link MS, Wang PJ, Estes NAM III. Cardiac arrhythmias and 
electrophysiologic observations in the athletes. In: Williams 
RA, eds. The Athlete and Heart Disease: Diagnosis, Evalua-
tion & Management. Philadelphia, PA: Lippincott Williams & 
Wilkins, 1999, p. 197-216.
 4. Link MS, Homoud MK, Wang PJ, Estes NAM III. Cardiac ar-
rhythmias in the athlete: The evolving role of electrophysiology. 
Current Sports Medicine Reports 2002:1;75-85.
 5. Link MS, Estes III NAM. Ventricular arrhythmias: In: Estes 
NAM, Salem DN, Wang PJ, eds. Sudden Cardiac Death in the 
Athlete. Armonk, NY: Future Publishing Company, Inc; 1998; 
253-275.
 6. Maron BJ, Epstein SE, Roberts WC. Cause of sudden death in 
competitive athletes. J Am Coll Cardiol 1986;7:204-214.
 7. Liberthson RR. Sudden death from cardiac causes in children 
and young adults. N Engl J Med 1996;334:1039-1044.
 8. Katcher M, Maron BJ, Homoud M. Risk profiling and screen-
ing strategies. In: Estes NAM, Salem DN, Wang PJ, eds. Sudden 
Cardiac Death in the Athlete. Armonk, NY: Future Publishing 
Company, Inc; 1998:57-87.
 9. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mu-
eller FO. Sudden death in young competitive athletes: clinical, 
demographic, and pathologic profiles. JAMA 1996;276:199-204.
 10. Krahn AD, Klein GJ, Yee R. The approach to the athlete with 
Wolff-Parkinson-White Syndrome: In: Estes NAM, Salem DN, 
Wang PJ, eds. Sudden Cardiac Death in the Athlete. Armonk, 
NY: Future Publishing Company, Inc; 1998; p. 237-252.
 11. Manolis AS, Wang PJ, Estes NAM III. Radiofrequency cath-
eter ablation for cardiac tachyarrhythmias. Ann Intern Med 
SUDDEN DEATH IN THE ATHLETE
159
1994;121:452-461.
 12. Link MS, Wang PJ, Haugh CJ, et al. Arrhythmogenic right ven-
tricular dysplasia: clinical results with implantable cardioverter 
defibrillators: J Interv Cardiovasc Electrophysiol 1997;1:41-48.
 13. Thompson PD, Funk EJ, Carleton RA, Sturner WQ. Incidence 
of death during jogging in Rhode Island from 1975 through 
1980. JAMA 1982;247:2635-2638.
 14. Marenco JP, Wang PJ, Link MS, Homoud MK, Estes NAM III. 
Improving survival from sudden cardiac arrest: the role of the 
automated exertional defibrillator. JAMA 2001;285(9):1193-
1200.
 15. Link MS, Maron BJ, Wang PJ, Pandian NG, VanderBrink 
BA, Estes NA 3rd. Reduced risk of sudden death from chest 
wall blows (commotio cordis) with safety baseballs. Pediatrics 
2002;109:873-877.
 16. Maron BJ. Sudden death in young athletes. N Engl J Med 
2003;349:1064-1075.
 17. Coris EE, Sahebzamani F, Walz S, Ramirez AM. Automated 
external defibrillators in National Collegiate Athletic Associa-
tion Division I Athletics. Am J Sports Med 2004;32:744-754.
 18. Maron BJ, Chaitman BR, Ackerman MJ, et al. Working Groups 
of the American Heart Association Committee on Exercise, 
Cardiac Rehabilitation, and Prevention; Councils on Clinical 
Cardiology and Cardiovascular Disease in the Young. Recom-
mendations for physical activity and recreational sports partici-
pation for young patients with genetic cardiovascular diseases. 
Circulation 2004;109:2807-2816.
 19. Wichter T, Paul TM, Eckardt L, et al. Arrhythmogenic right 
ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ab-
lation, or ICD? Herz 2005;30:91-101
 20. Maron BJ, Zipes DP. Introduction: eligibility recommendations 
for competitive athletes with cardiovascular abnormalities-gen-
eral considerations. J Am Coll Cardiol 2005;45:1318-1321.
 21. Corrado D, Pelliccia A, Bjørnstad HH, et al; Study Group of 
Sport Cardiology of the Working Group of Cardiac Reha-
bilitation and Exercise Physiology and the Working Group of 
Myocardial and Pericardial Diseases of the European Society 
of Cardiology. Cardiovascular pre-participation screening of 
young competitive athletes for prevention of sudden death: 
proposal for a common European protocol. Consensus State-
ment of the Study Group of Sport Cardiology of the Working 
Group of Cardiac Rehabilitation and Exercise Physiology and 
the Working Group of Myocardial and Pericardial Diseases of 
the European Society of Cardiology. Eur Heart J 2005;26:516-
524.
 22. Corrado D, Basso C, Pavei A, Michieli P, Schiavon M, Thiene 
G. Trends in sudden cardiovascular death in young competitive 
athletes after implementation of a preparticipation screening 
program. JAMA 2006;296:1593-1601.
 23. Pelliccia A, Di Paolo FM, Corrado D, et al. Evidence for ef-
ficacy of the Italian national pre-participation screening pro-
gramme for identification of hypertrophic cardiomyopathy in 
competitive athletes. Eur Heart J 2006;27:2196-2200. 
